These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

732 related articles for article (PubMed ID: 25580570)

  • 1. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline.
    Gault VA; Lennox R; Flatt PR
    Diabetes Obes Metab; 2015 Apr; 17(4):403-13. PubMed ID: 25580570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DPP-4 inhibitors improve cognition and brain mitochondrial function of insulin-resistant rats.
    Pintana H; Apaijai N; Chattipakorn N; Chattipakorn SC
    J Endocrinol; 2013 Jul; 218(1):1-11. PubMed ID: 23591914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the independent and combined effects of sub-chronic therapy with metformin and a stable GLP-1 receptor agonist on cognitive function, hippocampal synaptic plasticity and metabolic control in high-fat fed mice.
    Lennox R; Porter DW; Flatt PR; Holscher C; Irwin N; Gault VA
    Neuropharmacology; 2014 Nov; 86():22-30. PubMed ID: 24998752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stable oxyntomodulin analogues exert positive effects on hippocampal neurogenesis and gene expression as well as improving glucose homeostasis in high fat fed mice.
    Pathak NM; Pathak V; Lynch AM; Irwin N; Gault VA; Flatt PR
    Mol Cell Endocrinol; 2015 Sep; 412():95-103. PubMed ID: 26048772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (Val(8))GLP-1-Glu-PAL: a GLP-1 agonist that improves hippocampal neurogenesis, glucose homeostasis, and β-cell function in high-fat-fed mice.
    Lennox R; Porter DW; Flatt PR; Gault VA
    ChemMedChem; 2013 Apr; 8(4):595-602. PubMed ID: 23138973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice.
    Waget A; Cabou C; Masseboeuf M; Cattan P; Armanet M; Karaca M; Castel J; Garret C; Payros G; Maida A; Sulpice T; Holst JJ; Drucker DJ; Magnan C; Burcelin R
    Endocrinology; 2011 Aug; 152(8):3018-29. PubMed ID: 21673098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FGF21 and DPP-4 inhibitor equally prevents cognitive decline in obese rats.
    Sa-Nguanmoo P; Tanajak P; Kerdphoo S; Jaiwongkam T; Wang X; Liang G; Li X; Jiang C; Pratchayasakul W; Chattipakorn N; Chattipakorn SC
    Biomed Pharmacother; 2018 Jan; 97():1663-1672. PubMed ID: 29793329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential antidiabetic efficacy of incretin agonists versus DPP-4 inhibition in high fat fed mice.
    Lamont BJ; Drucker DJ
    Diabetes; 2008 Jan; 57(1):190-8. PubMed ID: 17928394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
    Herman GA; Bergman A; Stevens C; Kotey P; Yi B; Zhao P; Dietrich B; Golor G; Schrodter A; Keymeulen B; Lasseter KC; Kipnes MS; Snyder K; Hilliard D; Tanen M; Cilissen C; De Smet M; de Lepeleire I; Van Dyck K; Wang AQ; Zeng W; Davies MJ; Tanaka W; Holst JJ; Deacon CF; Gottesdiener KM; Wagner JA
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4612-9. PubMed ID: 16912128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dipeptidyl peptidase-4 inhibitor decreases abdominal aortic aneurysm formation through GLP-1-dependent monocytic activity in mice.
    Lu HY; Huang CY; Shih CM; Chang WH; Tsai CS; Lin FY; Shih CC
    PLoS One; 2015; 10(4):e0121077. PubMed ID: 25876091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positive interplay between FFAR4/GPR120, DPP-IV inhibition and GLP-1 in beta cell proliferation and glucose homeostasis in obese high fat fed mice.
    Owolabi AI; Corbett RC; Flatt PR; McKillop AM
    Peptides; 2024 Jul; 177():171218. PubMed ID: 38621590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained high-fat diet modulates inflammation, insulin signalling and cognition in mice and a modified xenin peptide ameliorates neuropathology in a chronic high-fat model.
    Denver P; Gault VA; McClean PL
    Diabetes Obes Metab; 2018 May; 20(5):1166-1175. PubMed ID: 29316242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic effects of the dipeptidyl peptidase-IV inhibitor, sitagliptin, on non-alcoholic steatohepatitis in FLS-ob/ob male mice.
    Onoyama T; Koda M; Okamoto T; Kishina M; Matono T; Sugihara T; Murawaki Y
    Mol Med Rep; 2015 Nov; 12(5):6895-902. PubMed ID: 26397061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates High-fat Induced Cognitive Decline in Tauopathy Model Mice.
    Nakaoku Y; Saito S; Yamamoto Y; Maki T; Takahashi R; Ihara M
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel dual incretin agonist peptide with antidiabetic and neuroprotective potential.
    Pathak NM; Pathak V; Gault VA; McClean S; Irwin N; Flatt PR
    Biochem Pharmacol; 2018 Sep; 155():264-274. PubMed ID: 30028989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, attenuates apoptosis of vascular smooth muscle cells and reduces atherosclerosis in diabetic apolipoprotein E-deficient mice.
    Li B; Luo YR; Zhang Q; Fu SH; Chen YD; Tian JW; Guo Y
    Vascul Pharmacol; 2021 Oct; 140():106854. PubMed ID: 33781961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Divergent effects of liraglutide, exendin-4, and sitagliptin on beta-cell mass and indicators of pancreatitis in a mouse model of hyperglycaemia.
    Mondragon A; Davidsson D; Kyriakoudi S; Bertling A; Gomes-Faria R; Cohen P; Rothery S; Chabosseau P; Rutter GA; da Silva Xavier G
    PLoS One; 2014; 9(8):e104873. PubMed ID: 25119717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short and Long Term Effects of a DPP-4 Inhibitor Versus Bedtime NPH Insulin as ADD-ON Therapy in Patients with Type 2 Diabetes.
    da Silva GM; Nogueira KC; Fukui RT; Correia MR; Dos Santos RF; da Silva ME
    Curr Pharm Des; 2016; 22(44):6716-6721. PubMed ID: 27928958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice.
    Matsubara J; Sugiyama S; Sugamura K; Nakamura T; Fujiwara Y; Akiyama E; Kurokawa H; Nozaki T; Ohba K; Konishi M; Maeda H; Izumiya Y; Kaikita K; Sumida H; Jinnouchi H; Matsui K; Kim-Mitsuyama S; Takeya M; Ogawa H
    J Am Coll Cardiol; 2012 Jan; 59(3):265-76. PubMed ID: 22240132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.